Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05635708
Title field or adapter rule
{'original_value': 'Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At
2026-10-31T23:27:28.011033+00:00
Published At
2026-10-30T00:00:00+00:00
Record Updated At
2026-10-30
Source Retrieved At
2026-10-31T22:18:03.495925+00:00
Timestamp Basis
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Non-small Cell Lung Cancer", "Metastatic Non-small Cell Lung Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId
"NCT05635708"
protocolSection.identificationModule.officialTitle
"Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct
null

Study condition terms

  • Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Non-small Cell Lung Cancer (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

  • {'armGroupLabels': ['Sub-study 1: Arm 2A', 'Sub-study 1: Arm 3A', 'Sub-study 1: Reference Arm Tislelizumab alone', 'Sub-study 2: Arm 1B', 'Sub-study 2: Arm 2B', 'Sub-study 2: Arm 3B', 'Sub-study 2: Reference Arm'], 'description': 'Administered by intravenous infusion', 'name': 'Tislelizumab', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Sub-study 2: Arm 1B'], 'description': 'Administered by intravenous infusion', 'name': 'BGB-A445', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Sub-study 1: Arm 2A', 'Sub-study 2: Arm 2B'], 'description': 'Administered by intravenous infusion', 'name': 'LBL-007', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Sub-study 2: Arm 1B', 'Sub-study 2: Arm 2B', 'Sub-study 2: Arm 3B', 'Sub-study 2: Reference Arm'], 'description': "Investigator's choice; administered by intravenous infusion", 'name': 'Carboplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Sub-study 2: Arm 1B', 'Sub-study 2: Arm 2B', 'Sub-study 2: Arm 3B', 'Sub-study 2: Reference Arm'], 'description': "Investigator's choice; administered by intravenous infusion", 'name': 'Cisplatin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Sub-study 2: Arm 1B', 'Sub-study 2: Arm 2B', 'Sub-study 2: Arm 3B', 'Sub-study 2: Reference Arm'], 'description': "Investigator's choice; administered by intravenous infusion", 'name': 'pemetrexed', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Sub-study 2: Arm 1B', 'Sub-study 2: Arm 2B', 'Sub-study 2: Arm 3B', 'Sub-study 2: Reference Arm'], 'description': "Investigator's choice; administered by intravenous infusion", 'name': 'Paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Sub-study 2: Arm 1B', 'Sub-study 2: Arm 2B', 'Sub-study 2: Arm 3B', 'Sub-study 2: Reference Arm'], 'description': "Investigator's choice; administered by intravenous infusion", 'name': 'Nab paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Sub-study 1: Arm 3A', 'Sub-study 2: Arm 3B'], 'description': 'Administered Orally', 'name': 'BGB-15025', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

  • Tislelizumab (protocolSection.armsInterventionsModule.interventions[].name)
  • BGB-A445 (protocolSection.armsInterventionsModule.interventions[].name)
  • LBL-007 (protocolSection.armsInterventionsModule.interventions[].name)
  • Carboplatin (protocolSection.armsInterventionsModule.interventions[].name)
  • Cisplatin (protocolSection.armsInterventionsModule.interventions[].name)
  • pemetrexed (protocolSection.armsInterventionsModule.interventions[].name)
  • Paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)
  • Nab paclitaxel (protocolSection.armsInterventionsModule.interventions[].name)
  • BGB-15025 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.